- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Stanford Scientists Develop Groundbreaking Universal Nasal Vaccine
Spray protects against viruses, bacteria and allergies without needles
Published on Feb. 21, 2026
Got story updates? Submit your updates here. ›
Researchers at Stanford University have developed a revolutionary nasal spray vaccine that could protect against a wide range of respiratory illnesses, including COVID-19, influenza, pneumonia and even allergies. Unlike traditional vaccines that target specific pathogens, this new vaccine primes the immune system to respond rapidly to any invader, offering broad and long-lasting protection.
Why it matters
The potential impact of this universal vaccine is enormous, as it could dramatically transform medical practice by reducing the need for multiple annual vaccinations and providing a crucial first line of defense against emerging pandemic threats. If successful in human trials, this innovation could significantly improve public health outcomes and ease the burden on healthcare systems.
The details
The vaccine, called GLA-3M-052-LS+OVA, is administered as a nasal spray and contains components that stimulate specific receptor proteins, activating innate immune cells like macrophages in the lungs. These macrophages are put on 'amber alert,' ready to spring into action at the first sign of infection. The vaccine also includes a harmless antigen, ovalbumin, which further recruits immune cells and prolongs the heightened state of readiness for weeks to months.
- The vaccine has only been tested in mice so far.
- Researchers are aiming to begin human trials, but estimate it could be 5-7 years before the vaccine is widely available.
The players
Dr. Bali Pulendran
The lead researcher on the project at Stanford University, who envisions a future where a single annual nasal spray could protect individuals from a wide range of respiratory viruses, bacteria and allergies.
Stanford University
The institution where the groundbreaking universal nasal vaccine was developed.
Dr. Daniela Ferreira
A vaccinologist at the University of Oxford who described the study as 'really exciting' and a potential 'major step forward' in protecting against common respiratory infections.
Dr. Brendan Wren
A microbiologist at the London School of Hygiene and Tropical Medicine who acknowledged the ambitious nature of the research but suggested the team may have 'hit on a new concept for vaccination.'
What’s next
Researchers are aiming to begin human clinical trials to determine the safety and efficacy of the universal nasal vaccine, but estimate it could still be 5-7 years before it is widely available to the public.
The takeaway
The development of this groundbreaking universal respiratory vaccine represents a significant leap forward in the fight against infectious diseases and allergies. If successful in human trials, it could dramatically transform medical practice by providing a single, needle-free solution to protect against a wide range of threats, easing the burden on healthcare systems and improving public health outcomes.
